VYNE Therapeutics (NASDAQ:VYNE) Releases Earnings Results, Misses Estimates By $3.33 EPS

VYNE Therapeutics (NASDAQ:VYNE) issued its quarterly earnings data on Thursday. The company reported ($3.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($3.33), FiscalAI reports. VYNE Therapeutics had a negative net margin of 4,726.21% and a negative return on equity of 70.42%. The company had revenue of $0.10 million for the quarter, compared to the consensus estimate of $0.20 million.

VYNE Therapeutics Trading Down 0.8%

VYNE stock traded down $0.23 during trading hours on Friday, hitting $28.32. 93,278 shares of the stock traded hands, compared to its average volume of 44,151. The stock has a 50-day simple moving average of $32.62 and a 200 day simple moving average of $31.48. The company has a market cap of $18.98 million, a P/E ratio of -74.54 and a beta of 2.00. VYNE Therapeutics has a one year low of $14.03 and a one year high of $79.75.

VYNE Therapeutics Announces Dividend

The company also recently announced a special dividend, which was paid on Thursday, July 23rd. Investors of record on Wednesday, July 22nd were paid a dividend of $19.00 per share.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of VYNE Therapeutics in a research report on Monday, May 4th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.

Institutional Investors Weigh In On VYNE Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. XTX Topco Ltd bought a new position in shares of VYNE Therapeutics during the 4th quarter valued at about $46,000. Boothbay Fund Management LLC bought a new stake in shares of VYNE Therapeutics in the 2nd quarter worth approximately $176,000. Jane Street Group LLC bought a new stake in shares of VYNE Therapeutics in the 2nd quarter worth approximately $206,000. Two Sigma Investments LP acquired a new stake in VYNE Therapeutics during the third quarter valued at approximately $74,000. Finally, Geode Capital Management LLC lifted its stake in VYNE Therapeutics by 64.2% during the fourth quarter. Geode Capital Management LLC now owns 225,152 shares of the company’s stock valued at $131,000 after purchasing an additional 88,030 shares during the last quarter. 83.78% of the stock is owned by institutional investors and hedge funds.

VYNE Therapeutics Company Profile

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.